Emergence of *Staphylococcus epidermidis* Clinical Isolates with Resistance to Both Mupirocin and Fusidic Acid

Chunchan Lin¹, Shuying Chen¹, Ye Jin¹, Jingjing Duan¹, Zhihao Hao¹, Shanshan Wang¹, Yinjuan Guo¹, Longhua Hu², Liangxing Wang³ and Fangyou Yu⁴,*

¹Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
²Department of Clinical Microbiology, The Second Affiliated Hospital of Nanchang University, Nanchang, China
³Department of Respiratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
⁴Department of Laboratory Medicine, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China
*Corresponding author: Department of Laboratory Medicine, Shanghai Pulmonary Hospital, Tongji University, School of Medicine, Shanghai 200001, China. Tel: +86-021-68480522, Email: wzjxyfy@163.com

Received 2017 October 10; Revised 2018 August 06; Accepted 2018 August 07.

**Abstract**

**Background:** In the recent decades, mupirocin and fusidic acid (FA) have become important antimicrobial agents for skin and soft tissue infections (SSTIs) and the eradication of staphylococci colonization.

**Objectives:** The present study aimed at determining the role of mupirocin and FA resistance in controlling *Staphylococcus epidermidis* infections and eradication of staphylococci colonization.

**Methods:** This study was conducted between January 2012 and December 2015, at a tertiary hospital in Wenzhou, east China, on 711 *S. epidermidis* clinical isolates collected consecutively from various specimens of inpatients. Polymerase chain reaction (PCR) and DNA sequencing were used to identify *mupA* conferring high-level mupirocin resistance and *fusA* mutations. Multi-locus sequence typing (MLST) based on nucleotide sequencing of seven housekeeping genes revealed distinct related clones of methicillin-resistant *S. epidermidis* (MRSE), as clinically significant isolates.

**Results:** Twelve FA-resistant *S. epidermidis* clinical isolates were positive for *fusB*, while only one was positive for *fusC*. All six *S. epidermidis* isolates with low-level mupirocin resistance were negative for *mupA*. However, 23 (35.38%) of 65 isolates with high level of resistance to mupirocin were found to carry this gene. Surprisingly, among 31 isolates with both mupirocin and FA resistance, only two were positive for *fusB* and only six were positive for *mupA*. More than 50% of the resistance for 71 mupirocin-resistant isolates and 56 FA-resistant isolates to non-β-lactam included erythromycin, clindamycin, ciprofloxacin, gentamicin and trimethoprim-sulfamethoxazole. Among 31 *S. epidermidis* isolates with both mupirocin and FA resistance, 15, three, and two belonged to ST2, ST466, and ST23, respectively. ST125 and ST130 were found in one isolate, each. All 15 ST2 *S. epidermidis* isolates were MRSE with high-level resistance to mupirocin (MICs > 256 mg/L), with similar resistance patterns.

**Conclusions:** Taken together, the present study is the first report of resistance to both mupirocin and FA among *S. epidermidis* isolates. Dissemination of *S. epidermidis* ST2 clone with both FA and mupirocin resistance can cause trouble in controlling *S. epidermidis* infections and eradication of staphylococci colonization.

**Keywords:** *Staphylococcus epidermidis*, Mupirocin, Fusidic Acid, Resistance, Molecular Characteristics

1. **Background**

*Staphylococcus epidermidis* is the most important member of coagulase-negative staphylococci (CoNS) and a commensal bacteria, which is isolated prevalently from human epithelia (1). *Staphylococcus epidermidis* is part of the human epithelia microflora and usually has a benign relationship with the host. Colonization with *S. epidermidis* contributes to the maintenance of a healthy skin flora by competition with potentially harmful microorganisms (2). In the recent decades, however, with increasing use of in-dwelling or implanted medical devices and the increase of multi-morbid, elderly, and immunocompromised patients, *S. epidermidis* has emerged as an important opportunistic pathogen responsible for hospital-acquired infections, especially biofilm-associated infections (1).

*Staphylococcus epidermidis* is one of the often encountered biofilm-producing bacteria and the establishment of *S. epidermidis* as a nosocomial pathogen mainly depends on biofilm formation (2). Polysaccharide intercellular adhesin (PIA) encoded by icaADBC operon is a mediator of biofilm formation in *S. epidermidis* (3). Arginine catabolic
mobile element (ACME), a novel genomic island, can help this species colonize the human skin, mucosal surfaces, and in-dwelling medical devices (4). Furthermore, increasing resistance rates to clinically available antimicrobial agents are an even greater problem for *S. epidermidis*, which limits the therapeutic options (1, 5). Mupirocin is an important antibiotic for skin and soft tissue infections (SSTIs) and the eradication of staphylococci colonization by binding to the bacterial isoleucyl-tRNA synthetase enzyme and inhibiting protein synthesis (6). However, with the increasing use of mupirocin, low- and high-level mupirocin resistance among staphylococci isolates has been increasing (7).

Fusidic acid (FA) is a valuable alternative to vancomycin for infections caused by multi-drug resistant staphylococci, especially MRSA infections (8-10). However, there is a significant trend towards increased FA resistance among staphylococci with increased duration of use. Molecular typing of *S. epidermidis* isolates associated with nosocomial infections has shown considerable clonal diversity and is much less studied than that for *S. aureus* (11). Multi-locus sequence typing (MLST), based on nucleotide sequencing of seven housekeeping genes, revealed distinct related clones of Methicillin-Resistant *S. epidermidis* (MRSE) clinically significant isolates and showed a worldwide predominance of only a few hospital-associated epidemic clonal lineages (11). Clonal complex 2 (CC2) was a major genetic lineage among the population structure of hospital-acquired *S. epidermidis*, worldwide (12, 13). Limited information is available on the resistance of *S. epidermidis* clinical isolates to mupirocin and FA. The aim of the present study was to investigate the resistance rate of *S. epidermidis* isolates from hospitalized patients to mupirocin and FA.

### 2. Objectives

The present study aimed at determining mupirocin and FA resistance for controlling *S. epidermidis* infections and eradicating staphylococci colonization.

### 3. Methods

#### 3.1. Ethics Statement

The ethics committee of the first Affiliated Hospital of Wenzhou Medical University exempted this study from review, because the present study focused on bacteria (ID: 62697).

#### 3.2. Bacterial Isolates

Seven hundred and seventy-one non-duplicate *S. epidermidis* isolates were collected consecutively from various specimens of inpatients from January 2012 to December 2015 at the first Affiliated Hospital of Wenzhou Medical University in Wenzhou, east China. The isolates were identified as *S. epidermidis* using Gram staining, catalase test, coagulase test, and VITEK automatic microbiology analyzer (bioMérieux, Marcy l’Etoile, France).

#### 3.3. MRSE Identification

Polymerase chain reaction was used to detect whether the tested strains harbored meca, with MRSA N315, as the positive control strain. The strains carrying meca were defined as MRSE. Moreover, all the clinical strains were targeted for mupA by PCR assays.

#### 3.4. Screening for Mupirocin and FA Resistance

Mupirocin and FA minimum inhibitory concentration (MIC) values for *S. epidermidis* isolates were determined by an agar dilution method, in accordance with the CLSI guidelines. The *S. aureus* ATCC29213 was used as the control strain. *Staphylococcus aureus* isolates with MICs of 8 to 256 mg/mL and ≥ 512 mg/mL were defined as having low- and high-level resistance to mupirocin (7). The researchers defined *S. epidermidis* with MIC of > 256 mg/mL as having high-level resistance to mupirocin. The interpretive criterion of FA susceptibility for staphylococci is in accordance with the European Committee for Antimicrobial Susceptibility Testing (EUCAST) / British Society of Antimicrobial Chemotherapy (BSAC) criteria (susceptible, MIC < 2 µg/mL; resistant, MIC ≥ 2 µg/mL).

#### 3.5. Antimicrobial Susceptibility Testing for Mupirocin-Resistant Staphylococcus epidermidis Isolates

The susceptibility of the mupirocin- and/or FA-resistant *S. epidermidis* clinical isolates to commonly used antimicrobial agents and screening of MRSE was done using VITEK-2 compact automated microbiology analyzer platform (bioMérieux, Marcy l’Etoile, France), according to the manufacturer’s instructions. Results interpretation was in accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines (14). Antimicrobial agents included ciprofloxacin (5 µg), clindamycin (2 µg), erythromycin (15 µg), gentamicin (10 µg), rifampin (10 µg), tetracycline (30 µg), and trimethoprimsulfamethoxazole (1.25/23.75 µg). All antimicrobial disks were obtained from Oxoid Ltd., and *S. aureus* ATCC25923 was used as a quality control strain for antimicrobial susceptibility testing.
3.6. Detection of Mupirocin and FA Resistance Determinants

*mupA*, conferring high-level mupirocin resistance, was detected by PCR, as described previously (15). *fusA* mutations and acquired FA resistance determinants, including *fusB*, *fusC* and *fusD*, were detected by PCR assays with primers and reaction conditions described previously (16) and DNA sequencing.

3.7. MLST Typing

Multi-locus sequence typing for *S. epidermidis* isolates was performed by amplification of internal fragments of the seven housekeeping genes, including *arcC*, *aroE*, *gtr*, *mutS*, *pyrR*, *tpiA*, and *yqiL*, described previously (17). The PCR products of seven housekeeping genes, tested for MLST typing, were purified and sequenced. The numbers of alleles and sequence types were assigned using an online database (http://sepidermidis.mlst.net/).

3.8. Statistical Analysis

Prevalence of MRSE was analyzed using GraphPad Prism 7.0 software. Results were considered statistically significant if P-values were < 0.05.

4. Results

4.1. Prevalence of Mupirocin Resistance Among *S. epidermidis* Clinical Isolates

Among 711 *S. epidermidis* clinical isolates, 71 (9.99%) with mupirocin MICs ranging from 16 to > 256 mg/L were found to be resistant to mupirocin. Low- and high-level mupirocin resistance proportions were 0.84% (6/711) and 9.14% (65/711), including 71 mupirocin-resistant isolates, 66 (92.96%) and five (7.04%) MRSE and methicillin-susceptible *S. epidermidis* (MSSE) (Figure 1). In the present study, more than 50% of resistance for 71 mupirocin-resistant isolates to non-β-lactam included erythromycin (84.51%, 60/71), clindamycin (74.65%, h53/71), ciprofloxacin (63.38%, 45/71), gentamicin (67.61%, 48/71) and trimethoprim-sulfamethoxazole (71.83%, 51/71), while the resistance rates to rifampin (39.44%, 28/71) and tetracycline (18.31%, 13/71) were less than 50% (Table 1).

4.2. Prevalence of FA Resistance Among *S. epidermidis* Clinical Isolates

Among 711 *S. epidermidis* isolates, 56 (7.87%) with FA MICs ranging from 4 to 32 mg/L were resistant to FA. Fifty (89.29%, 50/56) and six (10.71%, 6/56) FA-resistant isolates were MRSE and MSSE (Figure 1). In the present study, FA-resistant isolates exhibited more than 50% of resistance rates to erythromycin (89.36%, 45/56), clindamycin (64.29%, 36/56), ciprofloxacin (58.93%, 33/56), gentamicin (64.29%, 36/56), and trimethoprim-sulfamethoxazole (66.07%, 37/56), yet less than 50% of the resistance was towards rifampin (46.43%, 26/56) and tetracycline (23.21%, 13/56) (Table 1).

4.3. Prevalence of Both Mupirocin and FA Resistance Among *S. epidermidis* Clinical Isolates

Of 711 *S. epidermidis* clinical isolates, 31 (4.4%) were resistant to both mupirocin (MICs > 256 mg/L) and FA (MICs ranging from 4 - 16 mg/L). The prevalence of both mupirocin and FA resistance among mupirocin- and FA-resistant isolates was 43.66% (31/71) and 55.36% (31/56). Of 31 isolates with both mupirocin and FA resistance, 27 and four were MRSE and MSSE (Figure 1). Ten and seven were isolated from blood and catheter. Thirty-one isolates were isolated from 17 wards, with four from the intensive care unit (ICU). Resistance to both mupirocin and FA was found among *S. epidermidis* isolates.
4.4. Detection of Mupirocin and FA Resistance Determinants

In the present study, as shown in Table 2, all six S. epidermidis isolates with low-level mupirocin resistance were negative for mupA. However, 23 (35.38%) of 65 isolates with high-level resistance to mupirocin were found to carry this gene. In the present study, 12 FA-resistant S. epidermidis clinical isolates were positive for fusA, while only one was positive for fusC. The fusA mutations and fusD were not found in any of the tested isolates.

Among 31 isolates with both mupirocin and FA resistance, only two were positive for fusB, conferring FA resistance and only six were positive for mupA, conferring high-level mupirocin resistance.

4.5. Molecular Characteristics of S. epidermidis Clinical Isolates with both Mupirocin and FA Resistance

Among 31 S. epidermidis isolates with both mupirocin and FA resistance, 15, three, and two belonged to ST2, ST466, and ST23, respectively (Table 2). ST125 and ST130 were found only in one isolate each. Nine isolates with different loci patterns did not match the available STs in an online database (http://sepidermidis.mlst.net/). All 15 ST2 S. epidermidis isolates were MRSE and had high-level resistance to mupirocin (MICs > 256 mg/L). The MICs of FA for 14 ST2 isolates was 16 mg/L. The resistance profiles of 15 S. epidermidis ST2 isolates was similar, with resistance to penicillin, ciprofloxacin, levofloxacin, rifampin, gentamicin and trimethoprim-sulfamethoxazole, and susceptibility to vancomycin, linezolid, nitrofurantoin, quinupristin/dalfopristin, tetracycline and teicoplanin. Twelve (80.00%) of the 15 ST2 isolates were resistant to erythromycin and clindamycin. Fifteen ST2 isolates were isolated from blood (7), catheter (4), sputum (2), urine (1) and ascites (1), and disseminated among eight wards from 2012 to 2015 (Table 2). However, all four isolates (three from blood and one from catheter) with resistance to both FA and mupirocin from the ICU belonged to ST2 (Table 2).

5. Discussion

A high prevalence (61%) of mupirocin resistance was found among CoNS isolates, collected from catheter-associated bloodstream infections in very preterm neonates (18). In vivo transfer of high-level mupirocin resistance from S. epidermidis to S. aureus was associated with failure of mupirocin prophylaxis (19). Rates of low- and high-level mupirocin resistance were 9.4% and 3.3% in S. epidermidis, reported by a multi-centre surveillance study, including 26 laboratories from Austria, Germany, and Switzerland in November 2001 (20), while in the present study this rate was 0.84% and 9.14%. Mupirocin resistance may be helpful in the spread of multidrug resistance through co-selection with other resistance genes. Previous reports found that mupirocin-resistant S. aureus isolates were multi-resistant to other antimicrobial agents, such as ciprofloxacin, clindamycin, and tetracycline (21, 22). Similarly, in present study, mupirocin-resistant S. epidermidis were also multi-drug resistant to other antimicrobial agents.

McLaws et al. reported a high prevalence (46%, 23/50) of resistance to FA in S. epidermidis clinical isolates (23). Twenty-five percent of methicillin-resistant CoNS and 15% of methicillin susceptible CoNS strains isolated from blood cultures of septicemic patients in Turkey were resistant to FA (24). Compared with reports mentioned above, the prevalence of FA in the present study was relatively low, as for the prevalence of both mupirocin and FA resistance among S. aureus clinical isolates. Doudoulakakis et al. reported that 95.2% (417/438) of mupirocin-resistant S. aureus isolates were associated with community-associated infections among children in Greece were resistance to FA (25). Park et al. reported that all 13 low-level mupirocin-resistant S. aureus isolates and five (55.6%) of nine high-level mupirocin-resistant S. aureus isolates were resistant to FA (26). Overall, 103 (15.5%) of 664 S. aureus isolates from the UK were resistant to both FA and mupirocin (high level) (27). However, both mupirocin and FA resistance among S. epidermidis isolates was not reported previously. The present study was the first report of resistance to both mupirocin and FA, among S. epidermidis isolates. Emergence of both mupirocin and FA resistance among staphylococci limits the choice of antimicrobial agents for the treatment of multidrug-resistant staphylococci infections, especially SSTIs. Both mupirocin and FA-resistant isolates were susceptible to nitrofurantoin, quinupristin/dalfopristin, linezolid, vancomycin, and teicoplanin.

A new isoleucyl-tRNA synthetase with many similarities to eukaryotic enzymes, encoded by plasmid-borne gene mupA, conferred high-level resistance in staphylococci (28). Two major FA resistance mechanisms, the alteration of the drug target site caused by mutations in fusA, encoding elongation factor G (EF-G) or rplF encoding ribosome protein L6, and the protection of the drug target site by FusB family proteins, including FusB, FusC, and FusD, were reported in S. aureus (8). In staphylococci, high-level FA resistance is usually associated with mutations in fusA, while low-level resistance is generally caused by plasmid-mediated resistance genes, including fusB, fusC and fusD (29). Colonized staphylococci on skin may be a reservoir for FA resistance genes (30). The monitor for presence of FA resistance genes among S. epidermidis should be helpful for preventing the dissemination of fusidic acid resis-
Surprisingly, low positive rate for fusB conferring FA resistance and mupA conferring high-level mupirocin resistance, indicated that new mechanisms may be associated with both mupirocin and FA resistance. Further studies are needed to investigate these new mechanisms.

The results of multi-locus sequence typing (MLST) revealed that the S. epidermidis ST2 clone with resistance to both FA and mupirocin had disseminated in the hospital of the current study. ST2 was the predominant clone among S. epidermidis clinical isolates worldwide (12, 13). A report from China showed that 91.7% (297/324) of S. epidermidis from the community and hospital environments belonged to clonal complex 2 (CC2) (13). Furthermore, CC2 comprised 74% of the S. epidermidis isolates from 17 national centers between 1996 and 2001 (12). The majority (62/71; 87.3%) of S. epidermidis clinical isolates from US hospitals belonged to CC2 (31). The current authors speculate that acquiring resistance to both FA and mupirocin, as well as multi-resistance to other antimicrobial agents, contributes to the spread of S. epidermidis ST2.

### Table 2. Characteristics of S. epidermidis Isolates with Resistance to Both FA and Mupirocin

<table>
<thead>
<tr>
<th>Stains</th>
<th>STs</th>
<th>Specimen</th>
<th>FA (mg/L)</th>
<th>Mupirocin (mg/L)</th>
<th>mupA</th>
<th>fusB</th>
<th>Ward</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>BP201</td>
<td>4</td>
<td>Drainage</td>
<td>4</td>
<td>&gt; 256</td>
<td>-</td>
<td>-</td>
<td>Pediatric</td>
<td>2012</td>
</tr>
<tr>
<td>BP202</td>
<td>23</td>
<td>Drainage</td>
<td>8</td>
<td>&gt; 256</td>
<td>-</td>
<td>-</td>
<td>Pediatric</td>
<td>2012</td>
</tr>
<tr>
<td>BP204</td>
<td>2</td>
<td>Sputum</td>
<td>32</td>
<td>&gt; 256</td>
<td>-</td>
<td>-</td>
<td>Gastroenterology</td>
<td>2012</td>
</tr>
<tr>
<td>BP205</td>
<td>2</td>
<td>Sputum</td>
<td>16</td>
<td>&gt; 256</td>
<td>-</td>
<td>-</td>
<td>Respiratory</td>
<td>2012</td>
</tr>
<tr>
<td>BP206</td>
<td>2</td>
<td>Sputum</td>
<td>16</td>
<td>&gt; 256</td>
<td>-</td>
<td>-</td>
<td>Neurology</td>
<td>2012</td>
</tr>
<tr>
<td>BP207</td>
<td>2</td>
<td>Wound exudate</td>
<td>32</td>
<td>&gt; 256</td>
<td>-</td>
<td>-</td>
<td>Pediatric</td>
<td>2012</td>
</tr>
<tr>
<td>BP208</td>
<td>2</td>
<td>Catheter</td>
<td>16</td>
<td>&gt; 256</td>
<td>-</td>
<td>-</td>
<td>Hepatobiliary Surgery</td>
<td>2013</td>
</tr>
<tr>
<td>BP209</td>
<td>125</td>
<td>Catheter</td>
<td>16</td>
<td>&gt; 256</td>
<td>-</td>
<td>-</td>
<td>Nephrology</td>
<td>2014</td>
</tr>
<tr>
<td>BP210</td>
<td>2</td>
<td>Drainage</td>
<td>8</td>
<td>&gt; 256</td>
<td>-</td>
<td>-</td>
<td>Nephrology</td>
<td>2014</td>
</tr>
<tr>
<td>BP211</td>
<td>2</td>
<td>Urine</td>
<td>16</td>
<td>&gt; 256</td>
<td>-</td>
<td>-</td>
<td>Infectious disease</td>
<td>2015</td>
</tr>
<tr>
<td>BP212</td>
<td>2</td>
<td>Blood</td>
<td>16</td>
<td>&gt; 256</td>
<td>-</td>
<td>-</td>
<td>ICU</td>
<td>2014</td>
</tr>
<tr>
<td>BP213</td>
<td>2</td>
<td>Blood</td>
<td>16</td>
<td>&gt; 256</td>
<td>-</td>
<td>-</td>
<td>ICU</td>
<td>2014</td>
</tr>
<tr>
<td>BP214</td>
<td>2</td>
<td>Catheter</td>
<td>16</td>
<td>&gt; 256</td>
<td>-</td>
<td>-</td>
<td>Dialysis</td>
<td>2014</td>
</tr>
<tr>
<td>BP216</td>
<td>2</td>
<td>Wound exudate</td>
<td>8</td>
<td>&gt; 256</td>
<td>-</td>
<td>-</td>
<td>Dialysis</td>
<td>2014</td>
</tr>
<tr>
<td>BP217</td>
<td>466</td>
<td>Drainage</td>
<td>16</td>
<td>&gt; 256</td>
<td>-</td>
<td>-</td>
<td>Cardiovascular</td>
<td>2015</td>
</tr>
<tr>
<td>BP218</td>
<td>2</td>
<td>Ascites</td>
<td>16</td>
<td>&gt; 256</td>
<td>-</td>
<td>-</td>
<td>Gastroenterology</td>
<td>2015</td>
</tr>
<tr>
<td>BP219</td>
<td>2</td>
<td>Blood</td>
<td>16</td>
<td>&gt; 256</td>
<td>-</td>
<td>-</td>
<td>ICU</td>
<td>2015</td>
</tr>
<tr>
<td>BP220</td>
<td>2</td>
<td>Catheter</td>
<td>16</td>
<td>&gt; 256</td>
<td>-</td>
<td>-</td>
<td>ICU</td>
<td>2015</td>
</tr>
<tr>
<td>BP221</td>
<td>23</td>
<td>Dialysate</td>
<td>16</td>
<td>&gt; 256</td>
<td>-</td>
<td>-</td>
<td>Nephrology</td>
<td>2015</td>
</tr>
<tr>
<td>BP222</td>
<td>2</td>
<td>Blood</td>
<td>16</td>
<td>&gt; 256</td>
<td>-</td>
<td>-</td>
<td>Dialysis</td>
<td>2015</td>
</tr>
<tr>
<td>BP223</td>
<td>2</td>
<td>Blood</td>
<td>16</td>
<td>&gt; 256</td>
<td>+</td>
<td>-</td>
<td>Comprehensive ward</td>
<td>2015</td>
</tr>
<tr>
<td>BP224</td>
<td>2</td>
<td>Blood</td>
<td>16</td>
<td>&gt; 256</td>
<td>+</td>
<td>-</td>
<td>Comprehensive ward</td>
<td>2015</td>
</tr>
<tr>
<td>BP225</td>
<td>2</td>
<td>Blood</td>
<td>16</td>
<td>&gt; 256</td>
<td>+</td>
<td>+</td>
<td>Comprehensive ward</td>
<td>2015</td>
</tr>
<tr>
<td>BP226</td>
<td>2</td>
<td>Catheter</td>
<td>16</td>
<td>&gt; 256</td>
<td>-</td>
<td>-</td>
<td>Cardiovascular ICU</td>
<td>2015</td>
</tr>
<tr>
<td>BP227</td>
<td>130</td>
<td>Ascites</td>
<td>16</td>
<td>&gt; 256</td>
<td>-</td>
<td>-</td>
<td>Nephrology</td>
<td>2015</td>
</tr>
<tr>
<td>BP228</td>
<td>2</td>
<td>Catheter</td>
<td>16</td>
<td>&gt; 256</td>
<td>+</td>
<td>+</td>
<td>Infectious disease</td>
<td>2015</td>
</tr>
<tr>
<td>BP229</td>
<td>2</td>
<td>Blood</td>
<td>16</td>
<td>&gt; 256</td>
<td>-</td>
<td>-</td>
<td>Nephrology</td>
<td>2015</td>
</tr>
<tr>
<td>BP230</td>
<td>2</td>
<td>Blood</td>
<td>16</td>
<td>&gt; 256</td>
<td>-</td>
<td>-</td>
<td>Comprehensive ward</td>
<td>2015</td>
</tr>
<tr>
<td>BP231</td>
<td>2</td>
<td>Tissue</td>
<td>16</td>
<td>&gt; 256</td>
<td>-</td>
<td>-</td>
<td>Hepatobiliary Surgery</td>
<td>2015</td>
</tr>
<tr>
<td>BP232</td>
<td>466</td>
<td>Catheter</td>
<td>16</td>
<td>&gt; 256</td>
<td>-</td>
<td>-</td>
<td>Proctology</td>
<td>2015</td>
</tr>
<tr>
<td>BP233</td>
<td>2</td>
<td>Blood</td>
<td>16</td>
<td>&gt; 256</td>
<td>+</td>
<td>-</td>
<td>Neurology</td>
<td>2015</td>
</tr>
</tbody>
</table>
clone. ST23 was found among linezolid-resistant S. epidermidis isolates (32, 33). In the present study, ST23 was identified in two S. epidermidis isolates with resistance to both mupirocin and FA. The present study first reported that ST23 was identified among S. epidermidis isolates, isolated from China. Although ST25 and ST30 exist in online databases (http://sepidermidis.mlst.net/), literature on S. epidermidis identified in two isolates (32, 33). In the present study, ST23 was identified among S. epidermidis isolates. Dissemination of S. epidermidis resistance to both mupirocin and FA among S. epidermidis isolates. Mupirocin resistance: clinical implications and potential alternatives for the eradication of MRSA. J Antimicrob Chemother. 2015;70(10):2681-92. doi: 10.1093/jac/dkt499. [PubMed: 26142407].


